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ABSTRACT
We applied a solution hybrid selection approach to
the enrichment of CpG islands (CGIs) and promoter
sequences from the human genome for targeted
high-throughput bisulfite sequencing. A single lane
of Illumina sequences allowed accurate and quanti-
tative analysis of  1 million CpGs in more than
21408 CGIs and more than 15946 transcriptional
regulatory regions. Of the CpGs analyzed, 77–84%
fell on or near capture probe sequences; 69–75% fell
within CGIs. More than 85% of capture probes suc-
cessfully yielded quantitative DNA methylation infor-
mation of targeted regions. Differentially methylated
regions (DMRs) were identified in the 50-end regula-
tory regions, as well as the intra- and intergenic
regions, particularly in the X-chromosome among
the three breast cancer cell lines analyzed. We
chose 46 candidate loci (762 CpGs) for confirmation
with PCR-based bisulfite sequencing and demonst-
rated excellent correlation between two data sets.
Targeted bisulfite sequencing of three DNA methyl-
transferase (DNMT) knockout cell lines and the
wild-type HCT116 colon cancer cell line revealed a
significant decrease in CpG methylation for the
DNMT1 knockout and DNMT1, 3B double knockout
cell lines, but not in DNMT3B knockout cell line. We
demonstrated the targeted bisulfite sequencing ap-
proach to be a powerful method to uncover novel
aberrant methylation in the cancer epigenome.
Since all targets were captured and sequenced as
a pool through a series of single-tube reactions, this
method can be easily scaled up to deal with a large
number of samples.
INTRODUCTION
DNA methylation plays an essential role in normal devel-
opment and is involved in the pathogenesis of a variety of
human diseases (1). The human genome is comprised of 3
billion bp of DNA, of which  30 million are CpG di-
nucleotides, the main sites of DNA methylation. Given
the GC frequency, however, the number of CpGs is
much lower than expected. One unique feature of the
mammalian genome is the presence of genomic regions
containing dense clusters of CpGs, called ‘CpG islands’
(CGIs). CGIs are associated with over half of the known
promoters. CpG methylation, occurring in CGIs, has
functional consequences, such as transcriptional repres-
sion or aberrant activation (2). Many tissue-speciﬁc
genes are known to be silenced by promoter methylation.
Accumulating evidence has also indicated that
hypermethylation of CGIs can be one of the most preva-
lent molecular events in human cancers (3,4).
The methylation status of DNA can be detected by sev-
eral methods including: (i) methylation-sensitive restric-
tion enzymes that only cut DNA at unmethylated
recognition sites; (ii) sodium bisulﬁte which converts un-
methylated cytosines to uracils but has no effect on
methylated cytosines; (iii) methylated or unmethylated
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These procedures are usually combined with genome-
screening techniques to examine DNA methylation on a
whole- or subgenome scale (6–9). With the rapid advances
in next-generation sequencing (NGS) technologies,
whole-genome shotgun bisulﬁte sequencing was success-
fully used to map the complete methylomes of several
human embryonic stem (ES) cell lines at the
single-methyl-cytosine resolution (10,11). The single
base-level analysis was instrumental for the discovery of
non-CpG methylation in ES cells (11). However, in order
to analyze a large number of clinical samples, technology
that is quantitative, high throughput, cost-effective and
both scalable and ﬂexible with respect to coverage is ex-
tremely desirable (12).
Several genomic enrichment (or targeted capture)
methods developed for whole-exome sequencing (13)
were recently applied to targeted bisulﬁte sequencing
(TBS) applications (12,14–16). Hodges and colleagues
demonstrated that bisulﬁte-converted DNA can be hybrid-
ized to an oligonucleotide capture array to enrich regions
of interest for TBS (16). Within 324 selected CGIs, 25000
CpGs were successfully sequenced. Deng and colleagues
designed approximately 30000 padlock probes to assess
methylation of approximately 66000 CpG sites within
2020 CGIs on human chromosomes 12 and 20 (15); Ball
and colleagues designed approximately 10000 padlock
probes to proﬁle approximately 7000 CpGs within the
ENCODE pilot project regions (14). Both studies demon-
strated that the TBS approach based on padlock probes
was highly speciﬁc and reproducible. However, due to the
reduced sequence complexity after bisulﬁte treatment, the
methods that directly enrich targets from bisulﬁte-
converted DNA by hybridization may have difﬁculty se-
lecting the optimal capture probes in the highly GC-rich
regions. Nautiyal and colleagues developed a unique
method for capturing target DNA via oligo-guided
ligation before bisulﬁte conversion (12). The methylation
status of more than 145000 CpGs from 5472 promoters
was determined using a microarray. One of the challenges
of this methodology is the construction of the capture
probe panels, which were prepared by single-plex PCR
reactions (12).
In this study, we present an approach that combines
solution-phase hybrid selection and massively parallel bi-
sulﬁte sequencing to proﬁle DNA methylation in targeted
CGIs and promoter regions. The solution hybrid selection
method was initially developed for capture-sequencing of
exons (17). However, successful hybrid selection of gen-
omic DNA coupled with bisulﬁte conversion has not been
demonstrated. In addition, the high GC content present in
the CGIs makes capturing these regions a challenge. We
designed 51551 highly speciﬁc capture probes and opti-
mized the solution hybrid selection method for TBS in the
CGIs and promoter regions across the human genome.
Using one lane of Illumina sequences, we can quantita-
tively determine the methylation status of  0.9–1 million
CpGs in more than 21408 CGIs and more than 15946
transcriptional regulatory regions. Single-base resolution
CpG methylation maps in the promoters of a large number
of genes in three breast cancer cell lines were generated.
Also, differential methylation in the 50-end of regulatory
regions, as well as the intra- and intergenic regions, par-
ticularly in the X-chromosome was identiﬁed. The method
developed was further tested using wild-type and DNA
methyltransferase (DNMT) deﬁcient colon cancer cell
lines and the results revealed novel CpG methylation
patterns in these cell lines.
MATERIALS AND METHODS
Preparation of biotin-labeled capture probes
The method for preparation of the biotinylated capture
probe is the very similar to the method described by
Gnirke et al. (17) with minor modiﬁcations. The oligo-
nucleotide library was purchased from Agilent
Technologies. It consisted of 51551 oligonucleotides of
the sequence 50-AGGACCGGATCAACTN160CATTGC
GTGAACCGA-30 with N160 indicating the capture
probe sequences (17). The information on the probes
(start and end positions of the probe sequences in the
human genome), which can reproducibly capture target
DNA is provided in Supplementary Table S1. The library
was resuspended in 100ml0 . 1   TE buffer (10mM Tris–
HCl, 0.1mM EDTA, pH 8.0). A 4ml aliquot was used
for the ﬁrst PCR ampliﬁcation in 100ml containing
800nmol dNTPs, 40pmol each of PCR primer eMIP_
CA_F (50-TGCCTAGGACCGGATCAACT-30) and
eMIP_CA_R (50-GAGCTTCGGTTCACGCAATG-30)
(18), and 5U Pfu TurboCx DNA polymerase
(Stratagene). The PCR conditions used were 5min dena-
ture at 94 C, followed by 20 cycles of 20s at 94 C, 30s at
55 C, 30s at 72 C and 5min ﬁnal extension at 72 C. The
PCR products were puriﬁed using a PCR cleanup kit
(Qiagen) and loaded on a 2% NuSieve 3:1 agarose gel
(Lonza). A 200-bp band was cut from the gel and puriﬁed
using a gel puriﬁcation kit (Qiagen). The gel-puriﬁed
DNA was diluted 1:1000 and kept at  80 C. To add the
T7 promoter, 8ml diluted PCR product was re-ampliﬁed
in 200ml aliquots containing 800nmol dNTPs, 40pmol
of each of PCR primer combination eMIP_T7_F (50-TAA
TACGACTCACTATAGGGAGGACCGGATCAACT-30)/
eMIP_CA_R (50-GAGCTTCGGTTCACGCAATG-30)
and eMIP_T7_R (50-TAATACGACTCACTATAGGGA
GAGCTTCGGTTCACGCAATG-30)/eMIP_CA_F (50-T
GCCTAGGACCGGATCAACT-30) and 5U Pfu
TurboCx DNA polymerase (Stratagene) in two separate
PCR reactions with the same conditions mentioned above.
The 215-bp PCR products were puriﬁed using a PCR puri-
ﬁcation kit (Qiagen). To generate the biotinylated RNA
probes, 1mg of the puriﬁed PCR products was used as
template in a 100ml in vitro transcription reaction using
a MAXIscript T7 kit, (Ambion). The template DNA
was removed by incubating for 15min with 1ml Turbo
DNase (Ambion). The reaction was stopped by adding
0.5M EDTA and the biotinylated RNA probes were
puriﬁed using a MEGAclear kit (Ambion). Biotinylated
RNA probes were kept in the presence of 1U/ml
SUPERase-In RNase inhibitor (Ambion) at  80 C.
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Genomic DNA was isolated from cancer cell lines using
DNeasy Blood and Tissue Kit (Qiagen). The genomic
DNA was randomly fragmented into 150–500-bp segments
using a Bioruptor (Diagenode). The sheared DNA was
repaired, and an adenine was added to the 30-end of the
DNA fragments. Pre-annealed Illumina sequencing adap-
tors containing 5-methyl-cytosine were ligated to both
ends of the DNA fragments according Illumina standard
protocols (Illumina). The sequencing library was then
puriﬁed with an Ampure XP Kit (Agencourt). About
20–30mg of DNA each from breast cancer cell lines
MCF10A, MCF7 and MDA-MB-231 were used to estab-
lish the protocols, which yielded roughly 12mg of ligated
fragment library that is enough for six capture reactions
for each cell line. To make the assay consistent, we at-
tempted to maintain a constant ratio of library DNA to
the amount of capture probes used during the hybridiza-
tion reaction. To investigate if the amount of input DNA
affects sequencing results, we performed bisulﬁte sequenc-
ing experiments using DNA obtained from 6, 3, 2 or 1
capture reactions. The details about the amount of cap-
tured DNA used in each experiment are listed in Table 1.
Hybrid selection of target DNA
The hybridization procedure was performed as previously
described (17). Brieﬂy, 5mg human Cot-1 DNA
(Invitrogen), 5mg Salmon sperm DNA (Invitrogen) and
1mg pair-end DNA library were mixed and adjusted to
7ml by vacuum drying. The mixture was denatured at
95 C for 5min, and annealed at 65 C for 5min. Then,
13ml of pre-warmed 2  hybridization solution (10 
SSPE, 10  Denhardt’s, 10mM EDTA and 0.2% SDS)
and 6ml of a freshly prepared mixture containing 1mg
biotinylated RNA probe and 20U SUPERase-In were
added at 65 C. The hybridization mixture was incubated
for 48h at 65 C. After the hybridization was ﬁnished, the
DNA:RNA hybrid was captured with 100ml of M-280
Streptavidin Dynabeads (Invitrogen) that had been
washed three times and resuspended in binding buffer
(200ml 1M NaCl, 10mM Tris–HCl, pH 7.5 and 1mM
EDTA). The bead/capture solution was rotated for
30min at the room temperature and then was pulled
down and washed once at room temperature for 15min
using 500mlo f1   SSC/0.1% SDS. The bead/capture
solution was again pulled down and washed three times
at 65 C for 10min using 500ml of 0.1  SSC/0.1%SDS.
For elution of the capture DNA, a portion of 0.2M
NaOH solution was added and incubated at room tem-
perature for 10min. The beads were pulled down and the
supernatant was transferred to a new tube containing 70ml
of neutralization buffer (1M Tris–HCl pH 7.5). The
captured DNA was desalted and puriﬁed using a Zymo
DNA Clean & Concentrator Kit (Zymo Research) and
eluted in 20ml. The neutralization step can be omitted,
and the DNA in 0.2M NaOH solution can be directly
used for bisulﬁte treatment. For each sample, six capture
reactions were performed with probes targeting the
Watson strand, and six reactions were performed for the
Crick strand. The captured DNA was pooled in a strand
speciﬁc manner and used in two separate bisulﬁte treat-
ment reactions.
Bisulﬁte conversion, PCR ampliﬁcation and Illumina
sequencing
Bisulﬁte treatment was performed on the captured DNA
using EZ DNA Methylation Kit (Zymo Research,
Orange, CA, USA) according to the manufacturer’s
Table 1. Summary of the targeted bisulﬁte sequencing experiments
Cell lines MCF10A MDA-
MB-231
MCF7-1
a MCF7-2
a MCF7 HCT116 1KO 3BKO DKO Normal
breast
MCF10A MDA-
MB-231
Number of captures 6 6 6 6 3 3 33321 1
Total number of raw
reads (M
b)
27.38 29.15 29.22 30.95 33.79 35.60 38.56 33.66 37.24 22.14 29.86 24.21
Total number of
mapped reads (M)
22.40 24.13 24.08 25.61 27.44 27.86 32.02 27.22 29.57 17.87 22.86 17.40
Mapping rate (%) 77.39% 79.55% 79.04% 79.00% 81.22% 78.26% 83.04% 80.87% 79.76% 80.68 76.56% 71.86%
Total number of CpGs
measured (M)
1.08 0.96 0.91 1.08 0.63 0.54 0.42 0.48 0.65 0.31 0.41 0.16
Average number of
reads per CpG
86 137 146 112 96 229 204 234 129 89 25 87
Number of CpGs on/
near probe (M)
0.84 0.75 0.76 0.84 0.36 0.45 0.31 0.40 0.41 0.17 0.12 0.03
On-target rate (%)
c 77.78% 78.94% 83.51% 77.78% 77.78% 83.33 73.80% 83.33% 63.07% 55.28% 29.27% 18.75%
Number of CGIs
mapped with reads
22370 22484 21862 22161 17714 19505 17655 18601 19476 11549 13922 5107
Number of CpGs
mapped on CGI (M)
0.77 0.69 0.70 0.75 0.34 0.43 0.30 0.38 0.39 0.12 0.12 0.03
Probes that mapped
with more than 10
reads
44567 45266 43709 44266 23681 26222 23306 24849 25747 14892 17996 5663
Probe success rate (%) 86.45% 87.81% 84.79% 85.87% 45.93% 50.87% 45.21% 48.20% 49.94% 28.89% 34.91% 10.99%
aThese are technical replicates.
bM: million.
cNumber of CpG on/near probe divided by the total number of CpG.
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ately for PCR or stored at  80 C. For the ﬁrst round of
PCR ampliﬁcation, the bisulﬁte-converted DNA pooled
from six capture reactions was ampliﬁed in 4 50ml ali-
quots by 10 cycles of PCR using the following reaction
mixture, 2.5U of uracil-insensitive Pfu TurboCx Hotstart
DNA polymerase (Stratagene), 5ml1 0   Pfu TurboCx
buffer, 2.5mM dNTPs, 25mM of each Pair End (PE)
Primers 1 and 2. Cycling conditions for the reaction
were: 95 C for 2min, 98 C for 30s, then 10 cycles of
98 C for 15s, 60 C for 30s and 72 C for 4min, ﬁnal ex-
tension at 72 C for 10min. In order to completely remove
the primer dimers, the PCR products were ﬁrst puriﬁed
using a Zymo DNA Clean & Concentrator Kit (Zymo
Research) followed by a second puriﬁcation with an
Ampure XP Kit (Agencourt). For the second round of
PCR ampliﬁcation, the ﬁrst PCR product was ampliﬁed
in 50ml volume using 14 cycles of PCR with the following
reaction mixture, 2.5U Phusion DNA polymerase
(Finnzyme), 10ml5   Phusion buffer HF, 1.5mM
dNTPs, 25mM of each Pair End (PE) Primers 1 and 2.
Cycling conditions for the reaction were: 98 C for 15s,
65 C for 30s and 72 C for 4min, ﬁnal extension at 72 C
for 5min. The PCR products were puriﬁed using a Zymo
DNA Clean & Concentrator Kit (Zymo Research) as well
as an Ampure XP Kit (Agencourt). The PCR products
were sequenced using an Illumina GAIIx according to
manufacturer’s protocol.
Amplicon sequencing using 454-GS-FLX
Bisulﬁte-PCR primers for 46 genes were designed using
the PRIMEGENSv2 software (19) and synthesized by
IDT in a 96-well format. The amplicon information is
listed in Supplementary Table S2. Bisulﬁte-modiﬁed
genomic DNA from MDA-MB-231 and MCF7 was
used as the template for PCR ampliﬁcation of the 46
genes. The individual PCR products were pooled
together, puriﬁed, end-repaired and ligated to the bar-
coded sequencing adaptors using 454 library construction
kits and sequenced according to the manufacturer’s proto-
cols (Roche 454 Life Sciences).
ChIP and ChIP-seq
ChIP experiments were carried out using a Magna ChIP
kit (Millipore) following the manufacturer’s suggested
protocols. For each ChIP experiment, 5 10
6 MDA-
MB-231 cells were cross-linked with 1% formaldehyde
at 37 C for 10min. The anti-trimethyl-H3K4 (Upstate,
no. 04-745) antibody was used. The ChIP-seq libraries
were prepared from 10ng of both Input and ChIP DNA
samples using a ChIP-seq sample preparation kit
(Illumina) according to the manufacturer’s protocol. The
libraries were sequenced on a GAII sequencer (Illumina)
at 36-bp read length. The raw sequencing reads were pro-
cessed and aligned against the human genome using
ELAND program (Illumina) and the peaks were identiﬁed
using MACS (20).
Bisulﬁte sequences alignment and methylation analysis
The sequence analysis was done using an in-house bio-
informatics analysis pipeline in which the raw bisulﬁte
sequencing reads generated using Illumina sequencing
were ﬁrst converted to ‘unmethylated reads’ via the con-
version of all Cs to Ts in silico. The unmethylated, con-
verted sequencing reads were then aligned to the two
copies of in silico converted human reference genome
(hg18) using SOAP2 (15). The results of both mappings
were combined, and any reads mapped against both copies
of converted reference were resolved by identifying their
strand based on the TCAG ratio and the mapping pos-
itions used accordingly. The clonal reads were not
removed when the sequencing reads were mapped to the
genome. The methylation level [(number of methylated)/
(number of methylated+number of unmethylated)] was
calculated after measuring the amount of methylation
(CG!CG) and unmethylation (CG!TG) in the CpG
position. The results were stored and can be visualized
using the UCSC Genome Browser. Cluster analyses and
statistical analyses were performed using Partek Genomic
Suites (Partek) and R. The genomic annotation was per-
formed using in-house Perl scripts. The 454-sequencing
reads were analyzed using BSmapper (http://sourceforge
.net/projects/bsmapper). The raw and processed sequenc-
ing data were submitted to NCBI gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo). The acces-
sion number is GSE26826 (http://www.ncbi.nlm.nih
.gov/geo/query/acc.cgi?acc=GSE26826).
RESULTS
The overall experimental approach is illustrated in
Figure 1a. A pool of single-stranded DNA oligonucleo-
tides was synthesized by Agilent Technologies’ oligo li-
brary synthesis (OLS) services. Each oligonucleotide
consisted of a target-speciﬁc 160-mer sequence ﬂanked by
15 bases of a universal primer sequence on each side to
allow PCR ampliﬁcation. After initial PCR, a T7
promoter was added on each side of the PCR product in
two separate PCR reactions. The double-stranded PCR
products were converted into two sets of complementary
biotin-labeled RNA probes by in vitro transcription (17),
which were used to capture Watson and Crick strands of
the genomic DNA in two separate capture reactions, re-
spectively. The captured DNA was pooled from several
hybridization reactions, treated with sodium bisulﬁte,
ampliﬁed by PCR and subsequently sequenced using an
Illumina GA IIx sequencer (Figure 1a).
We designed 51551 highly speciﬁc capture probes using
the following criteria: (i) one capture probe (160bp) for
every 500bp window within a given CGI across the
genome. CGIs <500bp only have one probe per island;
(ii) one capture probe per transcription start sites (TSS)
for all RefSeq genes. We implemented these criteria in the
PRIMEGENS-v2 software to search for unique 160-bp
segments within the targeted regions (19,21). A highly
stringent criterion for cross hybridization was used and
only highly speciﬁc probes were selected. A total of
35746 probes were successfully designed to target 23441
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Next, we designed 15805 probes to capture the regions
crossing the TSS ( 300bp) of 19369 RefSeq genes after
excluding genes that already contained the CGI that spa-
nned around the TSS. Overall, the capture probes targeted
over 8.2 million bases in the genome and overlap with
>80% of CGIs and the promoters of known genes in
the human genome.
Targeted bisulﬁte sequencing was performed on three
breast cancer cell lines, MCF7, MDA-MB-231 and
MCF10A. We obtained 23–30 million single-end 76-bp
sequencing reads for each cell line. The bisulﬁte sequences
were analyzed using an in-house bioinformatics analysis
pipeline. We mapped the raw reads to the in silico bisulﬁte-
converted human genome, and an average of  79%
unique mapping rate was achieved. As an example, the
typical bisulﬁte sequencing results and sequencing cover-
age proﬁles in the promoter CGI of HOXA9 are shown in
Figure 1b. The average sequencing depth per CpG is
between 86 and 146 across cell lines (Table 1). The
fraction of probes with at least half of the average abun-
dance is 52–54% (Figure 1c), which is comparable to
previous studies (15,17). Methylation levels for CpG
sites covered with at least 10 sequencing reads were ex-
tracted providing accurate quantiﬁcation for  1 million
CpGs. Overall, 77–84% of the CpGs measured in the
samples fell on or near capture probe sequences;
69–75% fell within CGIs. More than 85% of capture
probes successfully yielded quantitative DNA methylation
information of the targeted regions (Table 1). As expected,
 40% of CpGs were located in 50-end transcriptional
regulatory regions including promoters and 50-UTRs,
while <18% of CpGs were associated with repetitive se-
quences (Supplementary Figure S1). In all three cell lines
(Supplementary Table S1), 21408 CGIs and 15946 tran-
scriptional regulatory regions were captured and se-
quenced. Bisulﬁte treatment efﬁciency can be determined
by calculating the C to T conversion (rate for all cytosine
bases other than those in CpG dinucleotides (this includes
CpA, CpC or CpT dinucleotides). The bisulﬁte conversion
rate was estimated to be 98.3, 98.3 and 98.7% for MCF7,
MCF10A and MDA-MB-231, respectively.
Next, the amount of input DNA was decreased in order
to determine the effects on the performance of TBS
method based on solution capture. When half of the
amount of captured DNA (from three capture reactions)
was used for bisulﬁte treatment and subsequent Illumina
sequencing, the number of CpGs sequenced was reduced
by  45% (Table 1). The bisulﬁte sequence mapping rate
and the on-target rate did not change signiﬁcantly, indi-
cating that the speciﬁcity of the solution hybrid capture
was not affected by the amount of input DNA. However,
the sensitivity of the TBS approach was adversely affected.
When DNA from only a single capture reaction was used,
a signiﬁcant decrease in the number of probes that were
able to capture the target DNA was observed. Using
genomic DNA from a normal breast tissue sample
( 10mg of DNA), we were able to measure the methyla-
tion status of  0.3 million CpGs and 11549 CGIs.
To validate the measurement accuracy of the targeted
bisulﬁte sequencing, we ﬁrst compared the methylation
Figure 1. Targeted bisulﬁte sequencing. (a) Illustrated are the steps
involved in the preparation of biotinylated RNA capture probes (top
left and right), whole-genome fragment input library (top middle) and
hybrid selection-enriched output library (middle left and right). The
captured DNA was treated with sodium bisulﬁte, ampliﬁed by PCR
and sequenced using an Illumina GAIIx sequencer. (b) Examples of
targeted bisulﬁte sequencing using solution hybrid selection. The
tracks shown from the top to bottom are: sequences of the capture
probes; the DNA methylation level at each CpG site derived from
the bisulﬁte-sequencing reads; the sequencing depth at each CpG site;
RefSeq genes; and annotated CGIs in the UCSC genome browser. Red
and green colors indicate methylated and unmethylated-CpG sites, re-
spectively. MCF7-1 and MCF7-2 are technical replicates. For each
sample, two tracks (methylation level and read depth) are shown.
(c). Distribution of normalized abundance for the captured targets
shared among all samples. The x-axis is the normalized abundance of
each captured target, which is calculated by dividing the counts of the
target by the average counts of all targets. The y-axis is the fraction of
probes with coverage equal to or greater than the normalized coverage.
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we captured the forward and reverse strands separately
(Figure 1a), and CpG methylation is symmetric on the
two DNA strands, the accuracy of the assay can be
determined by comparing the methylation level of these
CpG sites on the two strands (15). For 41257 such CpG
sites that were covered by more than 100 sequencing
reads, the Pearson correlation coefﬁcient (R) was 0.955
(Figure 2a), despite the fact that there was little correl-
ation in the sequencing coverage at these CpG sites
between the two strands (Figure 2b). To conﬁrm the tar-
geted bisulﬁte sequencing results, we quantiﬁed the methy-
lation levels of 762 CpG sites from 46 randomly selected
PCR products using 454 sequencing (Figure 3a–d and
Supplementary Table S2). Correlation between the two
assays was very good, but not perfect, at the single-CpG
level (R=0.818 and 0.826 for MCF7 and MDA-MB-231,
respectively). From Figure 4 and Supplementary Table S2,
it is apparent that 454 amplicon sequencing often gave a
higher methylation measurement. In the MCF7 cell line,
>80% of 219 CpG sites containing different methylation
measurements were found to have greater methylation
levels when measured by 454 sequencing. Similar results
were obtained for the MDA-MB-231 cell line. The higher
methylation measurements indicated by 454 sequencing
could be due to selective ampliﬁcation of methylated
DNA (which is more GC rich than unmethylated DNA)
in the initial PCR reaction. However, when compared at
the amplicon level, the correlation between the two assays
was excellent (R=0.924 and 0.944 for MCF7 and MDA-
MB-231, respectively; Figure 4). To test the reproducibil-
ity of the capture system, we compared the methylation
measurements from two independent technical replicates.
Excellent correlation was observed (Figure 2c). Therefore,
the validation experiments demonstrate that the capture
sequencing approach is accurate and reproducible.
Using this method, we generated genome wide, single-
base resolution DNA-methylation maps in three of the
most commonly used breast cancer cell lines which have
been cited extensively in the literature. The overall methy-
lation levels of CpGs displayed a similar bimodal distri-
bution among the three cell lines, which is consistent with
previous reports (Supplementary Figure S2). To evaluate
the DNA methylation status of each targeted loci, we ﬁrst
Figure 2. Accuracy and reproducibility of the targeted bisulﬁte-sequencing approach. (a) The scatter plot shows a comparison of methylation
measurements from both strands of the same CpG sites. The methylation levels of the forward strand were plotted against the levels of the
reverse strand on 41257 CpGs covered by sequencing reads mapped to both strands. Representative data from MCF7-2 was used. (b) The
scatter plot shows the comparison of sequencing coverage between forward and reverse strands for the same CpG sites. The same set of CpGs
are used in both panels (a and b). (c) Comparison of the methylation levels between two technical replicates of MCF7. The same DNA sample from
MCF7 was processed on a different day and sequenced in different batches. The data was plotted with increases in read depth per CpG. An increased
Pearson correlation coefﬁcient was observed, indicating that the read depth affects the consistency of the methylation data slightly.
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by the capture probes, and then took an average of the
methylation values of all CpGs within the 500-bp window.
The average methylation value was assigned to each target
loci. The methylation levels of 42460 loci and their anno-
tations are included in Supplementary Table S1. We split
these targeted loci into three main categories: 50-end of
known genes (27996 loci), intragenic regions including
the body and 30-end of genes (8921 loci), and intergenic
regions (5472 loci). The distribution of the average methy-
lation levels of target loci displayed a similar trend to
the distribution at the single-CpG level (Figure 5a).
However, the patterns of distribution seemed to depend
on their functional annotations, and are very similar
between the three cell lines, except the X-chromosome.
A signiﬁcantly higher number of unmethylated loci were
observed in the X-chromosome of MDA-MB-231 cells
when compared to other cell lines (Figure 4a). Cluster
analysis grouped the MDA-MB-231 and MCF10A cell
lines together when the methylation data from 50-end,
intra- and intergenic loci was used. However, cluster
analysis using methylation data from the X-chromosome-
grouped MCF7 and MCF10A together (Figure 5b), sep-
arating them from the triple negative and aggressive
Figure 3. Conﬁrmation of the targeted bisulﬁte-sequencing results by 454 amplicon bisulﬁte sequencing in MCF7 and MDA-MB-231 cells.
(a–d) Differential DNA-methylation patterns in the CpGs of four representative amplicons are shown. The browser tracks shown in each panel
from top to bottom are: the DNA methylation level at each CpG site derived from the bisulﬁte-sequencing reads; Ref-Seq genes; and annotated CGIs
in the UCSC genome browser. Red and green colors indicate methylated and unmethylated CpG sites, respectively. The bar graphs show the
comparison between two methods for the same four candidate genes. The x-axis is the CpG position in each amplicon, y-axis indicates the percentage
of methylation.
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regions (DMRs) can be identiﬁed in the 50-end regulatory
regions, as well as the intra- and intergenic regions, par-
ticularly in the X-chromosome among the three cell lines
(Figure 5b and Supplementary Figure S3).
We identiﬁed 1155, 2133 and 985 methylated genes with
average methylation levels equal or above 0.75 in
MCF10A, MCF7 and MDA-MB-231 cell lines, respect-
ively (Figure 5c). Surprisingly, MDA-MB-231 cells seem
to have the fewest number of methylated genes among
the three cell lines. These methylated genes were classi-
ﬁed according to their gene ontology (GO) category
(Supplementary Tables S3–S5). The single-CpG resolution
methylation maps of many known tumor suppressor genes
were established in the three cell lines. Supplementary
Figure S4 reveals the methylation patterns in the CGIs
of tumor suppressor genes such as SFRP1, SFRP2,
SOX17 and WIF-1 which are all inhibitors of WNT-
signaling pathway (Supplementary Figure S4A) as well
as several microRNAs that are embedded in the CGIs
(Supplementary Figure S4B). Supplementary Figure S5
illustrates differential methylation patterns in all four
HOX gene clusters. In addition, the DNA methylation
patterns correlated particularly well with histone modiﬁ-
cation data (Figure 5d). For instance, CpG methylation
was observed in the promoter of RASSF1A tumor sup-
pressor gene (the long transcript of RASSF1), but not in
the promoter of its alternative splice variant, RASSF1C
(the short form of RASSF1 transcript) (Figure 5d). This is
consistent with our previous ﬁnding that DNA methyla-
tion functioned in concert with histone modiﬁcations to
regulate gene expression of these speciﬁc transcripts (22).
GATA2 is another example, which has not been character-
ized previously. For both genes, the histone H3 lysine 4
tri-methylation (H3K4Me3) was associated with the un-
methylated promoters. Particularly for GATA2, the CGI
seems to be split in half and only the unmethylated region
is clearly overlapping with H3K4Me3.
To further test the robustness of the targeted bisulﬁte
sequencing method, we analyzed a group of DNMT
knockout cell lines derived from colon cancer cell line
HCT116 (23). These are isogenic cell lines with a single
gene defect (23–25). Using targeted bisulﬁte sequencing,
we analyzed 0.54, 0.42, 0.48 and 0.65 million CpGs in
DNMT1 knockout (1KO), DNMT3B knockout (3BKO)
and DNMT1, 3B double knockout (DKO) cell lines.
Similar to previous reports (23,24,26,27), the targeted
bisulﬁte sequencing data revealed a signiﬁcant decrease
in the number of methylated CpG sites in the DNMT1,
3B double knockout (DKO) cell line, but only modest de-
creases in the single knockout, 1KO and 3BKO, cell lines
(Figure 6a). Cluster analysis of the 129022 common CpGs
shared by all four cell lines revealed an interesting pattern
in which demethylation increased gradually from the
3BKO to DKO cell lines (Figure 6b). Approximately
30.5% of the 129022 CpGs were fully methylated
Figure 4. Scatter plots comparing the methylation levels of 762 CpG sites from 46 randomly selected genes determined by targeted bisulﬁte
sequencing, as well as 454 amplicon bisulﬁte sequencing. For a base-by-base comparison (left panel), the methylation results from two platforms
show good correlation in MCF7 (R=0.818) and MDA-MB-231 (R=0.826) cell lines, respectively. On a gene-by-gene basis (right panel), the
average methylation levels of 46 genes were highly correlated between two methods (R=0.924 and 0.944 for MCF7 and MDA-MB-231,
respectively).
e127 Nucleic Acids Research, 2011,Vol.39, No. 19 PAGE 8 OF 13Figure 5. DNA-methylation analysis in three breast cancer cell lines. (a) The histograms show the distribution of the average methylation levels of
target loci among different functional annotations (n, number of target loci). The target loci were annotated into three major categories: 50-end of
known genes (from  2000bp to+500bp of TSS), intragenic ( 500bp of TSS to the end of the transcript), and inter-genic regions. The methylation
levels are bimodally distributed, except for loci in the X-chromosome of MCF7 and MCF10A cells which were unimodally distributed. (b) Clustering
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(continued)(methylation levels>0.95) in the parental HCT116 cells.
Further analysis of the 38650 fully methylated CpGs
(mCpGs) in HCT116 showed that 88.3% of mCpGs dis-
played some degree of decreased methylation in at least
one DNMT knockout cell line. Almost half of the mCpGs
(17021 CpGs) had a methylation value of less than 0.5
(approximately  2-fold reduction in methylation level)
in at least one DNMT knockout cell line. We divided
the 17021 mCpGs into four different groups based on
the patterns of methylation in four colon cancer cell
lines (Figure 6c). Fifty-four percent of mCpGs were hypo-
methylated in both the 1KO and DKO cell lines (Class 2).
Of mCpGs, 34% were hypomethylated only in the DKO
cell line (Class 4). Of mCpGs, 9% were hypomethylated in
all three knockout cell lines (Class 1) and only 3% of
mCpGs had demethylation in both the 3BKO and DKO
cell lines (Class 3). Figure 6d illustrates some of the
demethylation patterns observed in the four cell lines.
The demethylated CpG sites were widely distributed across
the genome, affecting promoter and 50-UTR (24%, 4019
CpGs), gene body including exon, intron and 30-UTR
(33%, 5649 CpGs) and intergenic regions (43%, 7353)
(Figure 6c). The distribution of demethylated CpGs in
the aforementioned four classes did not change signiﬁcant-
ly among promoter, gene body and intergenic regions.
Only 386 demethylated CpGs were associated with repeti-
tive sequences that were widely distributed across the
subclass of repetitive sequences.
DISCUSSION
For the ﬁrst time, we have demonstrated that the solution
hybrid-capture approach can be successfully used for tar-
geted bisulﬁte sequencing. The solution hybrid selection
approach has recently become a popular method for target
enrichment. One unique feature of this protocol is to con-
vert the long oligonucleotides into biotin-labeled RNA
bait for capture of target DNA. This approach increases
the speciﬁcity of the hybridization capture, and makes the
capture process highly ﬂexible. However, an earlier study
indicated that targets having higher GC content resulted
in a much lower coverage (17). This systematic bias poses
a challenge for capturing CGI sequences. This challenge
was overcome by carefully selecting unique capture probes
sequences. We demonstrated that over 85% of the 51551
probes successfully captured their target DNA. Using a
single lane of Illumina sequences (20–30 million reads),
we can reproducibly quantify 0.9–1 million CpGs in the
human genome. This number is 6–36-fold higher than the
previously published results that use other sequence cap-
ture methods. Since the number of capture probes can be
easily expanded, the coverage of the TBS approach
described here can be signiﬁcantly increased. We also
showed that the TBS approach based on solution hybrid
selection was highly reproducible. The accuracy and pre-
cision of this approach was further conﬁrmed by bisulﬁte
sequencing analysis of 46 candidate loci using an inde-
pendent method. The current capture probe set focused
mainly on the promoter sequences and CGIs; however,
it can be easily expanded to include CGI shore,
enhancer and other regulatory regions.
Although whole-genome bisulﬁte sequencing is ideal for
methylome analysis, it remains cost-prohibitive for ana-
lyzing a large number of clinical samples. Meissner et al.
(28) developed a reduced representation bisulﬁte sequenc-
ing (RRBS) method for sub-genome bisulﬁte sequencing
using NGS and demonstrated its utility for analyzing
clinical samples. However, the analysis is only limited to
the MspI fragments in the genome. The solution hybrid
selection combined with bisulﬁte sequencing on NGS plat-
forms has clear advantages due to its ﬂexible and expand-
able probe design as well as the simple sample preparation
process which could be fully automated. Multiple
captured DNA samples can be bar-coded and sequenced
as a pool to meet the increased throughput of NGS.
Several other groups have also developed methods for
targeted genome-level bisulﬁte sequencing (12,14–16). Our
assays have several unique features when compared with
these methodologies. First, because the solution hybrid
selection procedure captures the DNA before bisulﬁte
conversion, the methylation status of the target sequence
does not factor into the capture probe design. Second, the
solution hybrid-capture approach is highly scalable and
ﬂexible with respect to coverage while maintaining the
high level of speciﬁcity. Finally, the capture probes can
be obtained commercially through Agilent’s eArray
service. One limitation of our current protocol is the re-
quirement of a relatively high amount of DNA for the
initial capture reaction. We reason that the following
factors might have been involved: (i) the targeted regions
are small (0.25% of the human genome), and the probe
density is rather low, one probe per 500-bp window. If one
probe failed to capture the DNA, there is no nearby probe
to compensate. (ii) A signiﬁcant amount of DNA was lost
during the library preparation and bisulﬁte modiﬁcation
steps. We sequenced the capture DNA from a single-
capture reaction before bisulﬁte treatment and found that
the coverage was similar and distributed more evenly than
the bisulﬁte sequencing of pooled DNA from multiple
capture reactions (data not shown). We predict that the
amount of DNA required can be reduced by designing a
larger and more densely distributed probe set, and by
further optimization of the library construction (29), hy-
bridization (30) and bisulﬁte treatment procedures.
Carrier DNA can also be added to the bisulﬁte treatment
Figure 5. Continued
of three breast cancer cell lines using the methylation data of target loci. The target loci were separated into three groups based on functional
annotation and analyzed separately. (c) Venn diagram showing the overlap between genes with at least one signiﬁcantly methylated 50-end locus
(methylation value > 0.75) in MCF10A, MCF7 and MDA-MB-231 cells. (d) DNA methylation and H3K4Me3 proﬁles in two representative
promoters (RASSF1 and GATA2) in MDA-MB-231 cells. The tracks shown from top to bottom are: the DNA methylation level at each CpG
site; ChIP-seq results of H3K4Me3 (the track in pink color); RefSeq genes; and annotated CGIs in UCSC genome browser. Red and green colors
indicate methylated and unmethylated CpG sites, respectively.
e127 Nucleic Acids Research, 2011,Vol.39, No. 19 PAGE 10 OF 13Figure 6. Targeted bisulﬁte-sequencing analysis of DNMT knockout colon cancer cell lines. (a) The histograms show distribution of CpG methy-
lation levels in DNMT knockout and wild-type HCT116 cell lines. (b) Cluster analysis of 129022 common CpGs shared by four cell lines. Blue
indicates a low level of methylation, while red indicates a high level of methylation. (c) Distribution of hypomethylated CpGs in HCT116 according
to the patterns of demethylation among cell lines (left panel); functional genome annotation (middle); and association with repetitive sequences (right
panel). (d) Patterns of demethylation in DNMT knockout colon cancer cell lines (1KO, 3BKO and DKO) and HCT116 cell line. Yellow, no
methylation; blue, methylation; the deﬁnition of each class was indicated in the text.
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ﬁte treatment and the subsequent puriﬁcation process (31).
To analyze primary tumor samples with a limited amount
of DNA, a bar-code could be assigned to multiple tumor
samples, the samples could then be pooled together, and
ﬁnally the capture reaction could be performed.
Using the targeted bisulﬁte-sequencing approach, we
generated single-base resolution methylation maps in
thousands of CGI and non-CGI promoters in breast
cancer cell lines, MCF10A, MCF7 and MDA-MB-231.
Interesting methylation patterns, such as localized shifts
between hyper- and hypomethylated states, were observed
in some promoters. For instance, although the promoter
region of HOXA9 is methylated in all three cell lines, the
ﬁrst exon is clearly differentially methylated (Figure 1b).
The biological signiﬁcance of this observation is unclear
and may deserve further investigation. However, we have
shown that DNA methylation may regulate the alternative
promoter usage and function in concert with histone
methylation (Figure 5d). We mapped a large number of
differentially methylated genes including microRNAs
(Supplementary Figure S4B). Differential methylation
was identiﬁed not only in the 50-end regulatory regions,
but also in the intra- and intergenic regions (Figure 5b).
Intriguingly, the cluster analyses of DNA methylation in
50-end regulatory regions, and inter- and intragenic regions
all grouped MCF10A and MDA-MB-231 together. This is
consistent with the classiﬁcation based on gene expression,
by which MDA-MB-231 and MCF10A were classiﬁed as
‘Basal B’ subtype, while MCF7 was classiﬁed as ‘Luminal’
subtype (32). Although MCF10A is a non-tumorgenic
breast epithelial cell line, we have found a large number
of methylated genes in this cell line. Interestingly, it seems
that DNA methylation patterns in the X-chromosome can
distinguish MCF10A from MDA-MB-231 cell line. A sig-
niﬁcantly higher number of under-methylated loci were
observed in MDA-MB-231 cells. Although we could not
determine if this observation is due to loss of
X-inactivation based on our data, it certainly deserves
further investigation in the future.
We further validated the ability of targeted bisulﬁte se-
quencing to detect changes in DNA methylation by using
DNA from wild-type and DNMT deﬁcient HCT116 colon
cancer cell lines. These DNMT deﬁcient cell lines have
been used as DNA-demethylation controls in numerous
studies (26,27,33,34). The targeted bisulﬁte sequencing
correctly identiﬁed a gradual increase in the number of
DNA hypomethylation events from the 3BKO, to 1KO,
to DKO cell lines. This result is in close agreement with
previous ﬁndings that utilized HPLC-based global methy-
lation analysis (23,24). The new sequencing results
indicated the critical role of DNMT1 in maintaining
global DNA methylation, as hypomethylated CpG sites
in the DKO cell line were most likely to be hypomethyl-
ated in the 1KO cell line as well. We have also identiﬁed
DNMT3B-speciﬁc demethylation patterns in a small group
of genomic loci (Figure 6d). These candidate loci may be
further investigated in the future in order to dissect the
role of each individual DNMT enzyme in establishing
CpG methylation patterns. In summary, the single-base
resolution DNA-methylation maps generated in the
study may become a valuable resource for gene-speciﬁc
epigenetic studies in these cell lines.
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